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Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is present
worldwide. Autoantibodies, in particular anti-mitochondrial antibodies (AMA) detected
by indirect immunofluorescence assays or newer solid phase immunoassays can detect
most, but not all individuals with PBC. Detection of antibodies to the anti-nuclear antigens
sp100 and gp210 can identify additional PBC patients, but some seronegative patients
remain, often resulting in delayed diagnosis and treatment. Antibodies to kelch-like
12 (KLHL12) and hexokinase 1 (HK-1) were recently identified as new biomarkers for
PBC and notably identify patients who are negative for conventional autoantibodies. To
become globally adopted, it is important to validate these new biomarkers in different
geographic areas. In the present study we evaluated the prevalence of anti-KLHL12
(measured by a KLHL12-derived peptide referred to as KL-p) and anti-HK-1 antibodies
by ELISA at five sites within Europe and North America and demonstrated the presence
of these antibodies in patients with PBC in all geographies.
Keywords: primary biliary cholangitis, autoantibodies, anti-mitochondrial antibodies, AMA-negative, hexokinase-
1, kelch-like 12
INTRODUCTION
For over 50 years, the detection of anti-mitochondrial antibodies (AMA) on rodent tissue sections
has remained the primary diagnostic biomarker for primary biliary cholangitis (PBC) in many
laboratories, and when performed and interpreted at expert centers, the assay is highly sensitive
and specific for PBC (1–3). It is clear however, that up to 15% of patients with clinically-proven
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PBC are AMA-negative by indirect immunofluorescence
(IIF) (4–7). Using recombinant proteins such as M2 (MIT3),
which incorporates the three immunodominant epitopes
recognized by AMA, namely the E2 subunits of pyruvate
dehydrogenase complex (PDC-E2), the branched chain 2-
oxo-acid dehydrogenase complex (BCOADC-E2), and the
2-oxo-glutareate dehydrogenase complex (OGDC-E2), can
result in increased sensitivity and the ability to detect additional,
but still not all, AMA-negative PBC patients (4, 8, 9). While
additional AMA-negative PBC patients can be identified by the
presence of anti-sp100 corresponding to the multiple nuclear dot
pattern by IIF on HEp-2 cells (AC-6 according to International
Consensus of ANA patterns, ICAP), anti-gp210 punctate nuclear
envelope by IIF on HEp-2 cells (AC-12 according to ICAP), and
anti-p62 antibodies, some PBC patients remain seronegative,
potentially resulting in delayed diagnosis and treatment (10–14).
Autoantibodies to kelch-like 12 protein (KLHL12) and to
hexokinase 1 (HK-1) were recently identified as novel biomarkers
in patients with PBC (15, 16). In a cohort of 366 patients with
PBC, ∼40 and 45% of 277 AMA-positive patients were positive
for anti-KLHL12 or anti-HK-1 antibodies respectively, while in
89 AMA-negative patients 53 and 42% were positive for anti-
KLHL12 or anti-HK-1 antibodies, respectively. The specificities
of both antibodies was 96–97% (15).
KLHL12 is part of a large, evolutionarily conserved
superfamily consisting of 66 KLHL genes (17). The various
Kelch proteins appear to be involved in multiple cellular
functions including cell structure, cellular communication,
transcriptional regulation, collagen export, and ubiquitination of
proteins through interaction with the E3-ligase cullin (17, 18).
HK-1 is an enzyme which localizes to the outer membrane
of mitochondria and phosphorylates glucose to yield glucose-
6-phosphate, as well as modulating cellular susceptibility to
apoptosis (19).
Although difficult to clearly establish, it appears that the
prevalence of PBC is increasing worldwide (20–22). While
AMA has a similar prevalence in PBC patients from different
geographies, the prevalence of anti-KLHL12 and anti-HK-1
antibodies in different geographic areas has not been reported. To
address this issue, we examined PBC sera collected from patients
in Eastern Europe, Western Europe, and Canada for the presence
of anti-KLHL12 and anti-HK-1 antibodies.
TABLE 1 | Frequency of anti-HK-1, anti-KL-p, and anti-HK-1 and/or anti-KL-p in each geographic cohort and in a combined cohort including all patients.
Anti-HK-1+ Anti-KL-p+ Anti-HK-1+ and/or KL-p+
Total Cohort N = No. (%) MIT3+ No. (%) MIT3– P- value No. (%) MIT3+ No. (%) MIT3– P-value No. (%) MIT3+ No. (%) MIT3– P-value
Barcelona 224 75/195 (38.5) 10/29 (34.5) 0.8379 49/195 (25.1) 3/29 (10.3) 0.0991 103/195 (52.8) 13/29 (44.8) 0.4341
Calgary 97 48/90 (53.3) 1/7 (14.8) 0.0592 23/90 (25.6) 2/7 (28.6) 1.000 59/90 (65.6) 3/7 (42.9) 0.2486
Edmonton 104 45/87 (51.7) 2/17 (11.8) 0.0028 22/87 (25.2) 2/17 (11.8) 0.3476 54/87 (62.1) 3/17 (17.6) 0.0014
Warsaw 41 12/26 (46.2) 3/15 (20.0) 0.1772 6/26 (23.1) 3/15 (20.0) 1.000 15/26 (57.7) 5/15 (33.3) 0.1971
Salamanca 21 9/16 (56.3) 2/5 (40.0) 0.6351 3/16 (18.8) 4/5 (80.0) 0.0251 9/16 (56.2) 4/5 (80.0) 0.6065
COMBINED 487 189/414 (45.7) 18/73 (24.7) 0.0008 103/414 (24.9) 14/73 (19.2) 0.3725 240/414 (58.0) 28/73 (38.4) 0.0022
P-values <0.5 are considered significant and indicated by bold type.
MATERIALS AND METHODS
Sera from a total of 487 patients with clinically documented
PBC or PBC/AIH overlap diagnosed according to European
Association for the Study of the Liver (EASL) guidelines were
collected at five expert clinical sites (Barcelona, Spain; Salamanca,
Spain; Calgary, Canada; Edmonton, Canada; Warsaw, Poland)
and tested for the presence of autoantibodies to HK-1 and a
KLHL12-derived immunodominant peptide, referred to as “KL-
p,” using research use only ELISA kits (QUANTA Lite R©, Inova
Diagnostics, San Diego, CA). All sera were also tested for anti-
M2 (MIT3) antibodies (subsequently referred to as anti-MIT3 for
simplicity) by ELISA (QUANTALite R© ELISA, InovaDiagnostics,
San Diego, CA). Specificity was assessed by testing 127 sera from
patients without PBC, including patients with primary sclerosis
cholangitis (PSC, n = 41), autoimmune hepatitis (AIH, n = 20),
AIH/PSC overlap (n = 12), various infectious diseases (n = 20),
colorectal cancer (n= 14), and healthy controls (n= 20).
Differences between the five cohorts was assessed by one-
way analysis of variance (ANOVA) using Krustal-Wallis test and
between specific geographic chorts using Mann-Whitney non-
parametric two-tailed t-test (Graphpad ver 5.03, San Diego, CA).
P-value <0.05 was considered significant.
RESULTS
Testing for anti-MIT3 antibodies showed that each cohort had
different frequencies of anti-MIT3 negative individuals (Calgary,
7.2%; Barcelona, 12.9%, Edmonton, 16.3%; Salamanca, 23.8%,
and Warsaw, 36.6%) (p = 0.0002). Overall anti-HK-1 antibodies
were found in 36.6–52.4% and anti-KL-p antibodies in from
22.0–33.3% of the cohorts. The specific prevalence of anti-HK-1
and KL-p antibodies at each site is summarized in Table 1.
As a result of the apparent heterogeneity of the cohorts, we
proceeded to examine the performance of the two biomarkers
after specimens were stratified by anti-MIT3 positivity. Anti-HK-
1 antibody positivity in anti-MIT3-positive individuals ranged
from 38.5–56.3% as detailed in Table 1. While the groups were
statistically different overall (ANOVA p = 0.0006), there was
no difference between some of the sites, for example Barcelona
and Edmonton (p = 0.8169). When all specimens from the
five cohorts were combined, anti-HK-1 antibody was positive
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in 45.7% (189/414) of the anti-MIT3-positive specimens, with a
specificity of 94.5% (120/127). Of the seven non-PBC specimens
that tested positive, four had a diagnosis of AIH, two colorectal
cancer, and one was an apparently healthy control. The likelihood
ratio (LR)+, LR-, positive predictive value (PPV), negative
predictive value (NPV), and Odds Ratio (OR) of anti-HK-1
antibodies for the combined cohort of all anti-MIT3-positive
specimens was 8.28, 0.58, 0.96, 0.35, and 14.40.
Anti-KL-p antibody positivity in the anti-MIT3-positive
specimens ranged from 18.8–25.6% (Table 1). Overall, when all
specimens were combined, anti-KL-p antibody was positive in
24.9% (103/414) of the anti-MIT3-positive specimens with a
specificity of 95.3% (121/127). As with anti-HK-1 antibodies,
while the groups were statistically different overall (ANOVA p
< 0.0001), several showed no statistical difference, again for
example Barcelona-Edmonton, Barcelona-Warsaw, Edmonton-
Warsaw (p = 0.9973, 0.4333, and 0.0868 respectively). The
LR+, LR-, PPV, NPV, and OR for anti-KL-p antibodies for the
combined cohort of anti-MIT3-positive specimens was 4.60, 0.79,
0.96, 0.18, and 5.80.
Examination of anti-MIT3-negative PBC patients in the five
cohorts showed a prevalence of anti-HK-1 antibodies ranging
FIGURE 1 | Prevalence of anti-HK-1 (A), anti-KL-p (B), and combined anti-HK-1/KL-p antibodies (C) in cohorts from five individual sites and combined cohort
consisting of all specimens tested (both anti-MIT3-positive and negative PBC specimens). Frequency in anti-MIT3-negative patients indicated by black diamonds and
frequency in anti-MIT3-positive patients by black dots. Venn diagram (D) showing overlap of anti-MIT3, anti-HK-1, and anti-KL-p antibodies. The cohort (n = 487)
contains patients with primary biliary cholangitis (PBC, n = 474), PBC-autoimmune hepatitis (AIH) overlap (n = 13), including both anti-MIT3-positive (n = 414) and
anti-MIT3-negative (n = 73) PBC samples.
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from 11.8–40.0% and anti-KL-p antibodies from 10.3 to 80.0%
(Table 1). Among all anti-MIT3-negative specimens from the
5 sites, anti-HK-1 antibodies were found in 18/73 (24.7%) and
anti-KL-p in 14/73 (19.2%) of the patients. Employing both
markers to examine the anti-MIT3-negative patients increased
the sensitivity to 38.4% (28/73) with a small decrease in specificity
to 91.3%.
The overlap of anti-MIT3, anti-HK-1, and anti-KL-p
antibodies is illustrated using a Venn diagram in Figure 1.
The addition of anti-HK-1 and anti-KL-p antibody testing to
anti-MIT3 antibody results increased the sensitivity from 85.0%
for anti-MIT3 alone to 90.8% for the combination of anti-MIT3,
anti-HK-1, and anti-KL-p for the total study cohort.
DISCUSSION
The incidence of PBC, like many other autoimmune diseases,
appears to be increasing worldwide (20–22). Environmental
factors have been suggested as one potential contributing cause
of the increasing incidence of PBC (3). In addition, better
diagnostics and better recognition of the disease, especially
during the often long asymptomatic phase, are also likely
involved in the apparent increased prevalence (23, 24). The
availability of new therapeutics such as obeticholic acid provides
an additional rationale to identify patients with PBC early in
the disease course, so that treatment and monitoring that might
slow, or ideally prevent progression can be instituted (22).
New biomarkers to help identify AMA or anti-MIT3-negative
PBC patients who may otherwise remain unrecognized, are
particularly important to help achieve this goal.
Despite the regular description of new biomarkers in the
literature, only a few contribute additional actionable clinical
value and are incorporated into routine clinical practice. We
have previously shown that anti-HK-1 and anti-KL-p antibodies
are present in both AMA-positive and, importantly, AMA-
negative patients (15). Our current results demonstrate that the
general prevalence of these autoantibodies is similar in 5 different
sites examined from North America and Europe. The pooled
prevalence of anti-HK-1 antibodies was 45.7% in anti-MIT3-
positive patients and 24.7% in anti-MIT3-negative patients. Anti-
KL-p antibodies were detected in 24.9% of the anti-MIT3-
positive patients and 19.2% of the anti-MIT3-negative patients.
Combined testing for both antibodies found 58.0% of the anti-
MIT3-positive and 38.4% of the anti-MIT3-negative patients
seropositive for one or both of the new antibodies. The new
biomarkers therefore may help to close the serological gap in
PBC patients. The prevalence of the markers appeared more
similar in the anti-MIT3-positive patients from the different sites
compared to the anti-MIT3-negative patients. This is reasonable
since the anti-MIT3-positive patients are likely a more clinically
homogeneous group compared to the anti-MIT3-negative group,
which may have a more heterogeneous phenotype. The small
sample size of several of the cohorts is also a clear limitation
of the study and likely contributes to some of the perceived
differences between cohorts. The higher prevalence of anti-HK-1
antibodies compared to anti-KL-p antibodies could be related to
the presence of HK-1 on the mitochondrial membrane, similar
to other PBC-related antigens. In contrast, explanation why
antibodies to KLHL12 are increased in patients with PBC remains
intriguing, but still unclear at present.
Early treatment of patients with PBC appears beneficial and,
therefore, addition of anti-KL-p and anti-HK-1 autoantibody
testing has the potential to decrease delays in diagnosis and
treatment (22). Although we did not examine the prevalence of
the antibodies in Asian and South American populations, these
studies are currently being organized. A key question remaining
is whether, in addition to their value in diagnosis, these antibodies
can be shown to be associated with particular clinical phenotypes
or outcomes. Preliminary results, so far only presented in
abstract form, suggest this may be the case for anti-HK-1
antibodies, where the presence of these antibodies at diagnosis
was associated with significantly increased levels of alkaline
phosphatase, alanine aminotransaminase, and gamma-glutamyl
transpeptidase compared to anti-HK-1 negative patients, as
well as with shorter transplant-free survival time (25). These
results are potentially of important clinical interest, however
additional validation and studies are now needed to confirm
their significance.
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